BPC-157 for Tendons and Ligaments: Research Review

Tendons are some of the slowest healing tissues in the human body. Limited blood supply, high mechanical stress and dense collagen architecture do not offer much help in accelerating healing. BPC-157 was tested on rat models of Achilles tendon transection, medial collateral ligament (MCL) rupture and detachment of the quadriceps tendon. The performance data includes biomechanical improvements measured by the load to failure, stiffness and Young's modulus. All data were taken from animals. In the article below we review every published tendon study and provide links to the raw articles so that the reader can consult the primary source.

Why Tendons Heal Slowly

The tendons play their function of connecting both muscle to bone and passing forces through the body. Tendons are composed mainly of collagen type I fibers arranged in parallel arrays and separated from each other by the tenocytes (the tendon cells). Tendons are poorly vascularized compared to muscle and skin. Achilles tendon, patellar tendon, and rotator cuff tendon are at risk for chronic overuse injuries due to their narrow vascular zones.

The Biology of Slow Repair

In the aftermath of injury, tendons go through 3 stages, namely inflammation (days 1-7), proliferation (days 7-21) and remodeling (weeks or months). The phase of proliferation involves the production of type III collagen at first, which is a weaker form of collagen than the future type I collagen. It may take 6 to 12 months to fully remodel tendon tissue. Also, even after this period repaired tendon tissue is seldom able to achieve the tensile strength of normal intact tendon tissues. As a result, tendon injuries are often recurrent.

The Achilles Tendon Transection Model

The Achilles transection model is the most comprehensive study of BPC-157 in tendons since it uses proper biomechanical assessment as the main outcome.

Krivic 2006 Study Design

A 2006 study by Krivic et al. surgically transected the Achilles tendon in rats and treated them with BPC-157 applied locally at the transection site or administered systemically via intraperitoneal injection. Control animals received saline. Tendons were harvested at 14 days post-surgery and subjected to biomechanical pull-to-failure testing on a materials testing machine.

Biomechanical Results

The tendons that received treatment with BPC-157 showed three different areas of improvement compared with the control tendons. The load to failure was greater, indicating that the tendon was able to tolerate a higher force before rupturing. Also, the stiffness was greater, which implies that it was more resistant to deformation when being loaded. The Young's modulus was better, evaluating the improvement of properties of the healing material. Histological examination also showed better organized collagen fibers in the treated specimens. Both local and systemic administration produced positive results, though local application was more effective in this experimental setup.

MCL and Other Ligament Models

The medial collateral ligament has also undergone research. Ligaments join bones together and they have a similar structure to tendons, which include dense collagen, very little blood supply, and a slow healing process.

Ligament-Specific Findings

MCL rupture studies have demonstrated effectiveness of BPC-157 in healing. Statistically significant reductions in inflammatory infiltrate, collagen organization, and tissue continuity at injury site were found in the ligaments treated with BPC-157 when compared with the saline controls. These data are in line with the findings of the studies involving Achilles tendon but are less rigorous since the method of histological assessment was employed rather than biomechanical testing.

Relevance to Common Knee Injuries

The MCL is one of the 4 main ligaments that provide stability to the human knee. MCL injuries occur frequently in contact sports and skiing. Compared to the ACL, the MCL has a better chance of healing due to its superior blood supply, although grade III tears may need surgical treatment. It has not yet been established whether improvements in the rat MCL model can be applied to humans. The forces acting on human knee ligaments are several orders of magnitude greater than those acting on rat ligaments. No research on human ligaments has been completed.

BPC-157 vs TB-500 for Tendon Repair

A 2025 study directly compared BPC-157 and TB-500 in an Achilles tendon injury model. This is one of the few head-to-head comparisons of these 2 peptides in the published literature.

Head-to-Head Comparison

The investigation analyzed healing effects of BPC-157 on tendon repair when used alone, TB-500 on its own, and both of them together. The outcomes of therapy with the two peptides alone were superior to saline treatment. However, combining the two peptides did not produce significant improvement over either peptide alone on any metric. This contradicts marketing claims about additive effects. The experiment was performed only once on rats and needed to be independently verified before drawing conclusions. For more information, consult BPC-157 vs TB-500 page.

Proposed Mechanisms of Action

Researchers have proposed several possible ways BPC-157 may accelerate tendon healing. None has been confirmed as the dominant mechanism.

Growth Hormone Receptor Upregulation

Research by a 2014 in-vitro study shows that BPC-157 elevates expression levels of growth hormone receptor (GHR) in tendon fibroblasts acting in a dose-dependent manner. The peptide further enhances cell movement via the FAK-paxillin pathway. Activation of GHR promotes collagen production and cell division in connective tissue. This observation links the effect of BPC-157 on tendons with the growth factor signaling rather than its direct interaction with collagen.

Angiogenesis at the Injury Site

A 2010 study reported increased angiogenesis in tendon and muscle tissue treated with BPC-157. New blood vessel formation addresses one of the primary barriers to tendon healing: insufficient blood supply to deliver nutrients and clear debris from the injury site. The peptide increased expression of VEGF and VEGFR2 in treated tissue. This pro-angiogenic effect is consistent across gut, skin, muscle and tendon models.

Nitric Oxide Pathway Interaction

BPC-157 affects the nitric oxide system in experimental animals. Nitric oxide contributes to the healing process of tendons because it modulates collagen production, activates immune cells and maintains the vascular tone in the area of injury. BPC-157 appears to stabilize nitric oxide levels rather than simply raising or lowering them, which may explain its positive effects in both ischemic and inflammatory injury models.

What the Data Does Not Show

To date, there has been no research investigating the uses and effects of BPC-157 on human tendon conditions, including tendonitis, tendinopathy, or post-surgical tendon healing. The Achilles transection model in rats involves the cutting of the tendon, which doesn’t resemble the chronic overuse models most people have. Tendinopathy is caused by degenerating collagen and not a simple transection. So it is still unclear if BPC-157 would be a useful method for treating degenerating tendons.

The follow-up time period in numerous studies is confined to just 14 days. No longer follow-up has been published. Human tissue remodeling has been observed to occur after a period of 6 and 12 months. A 14-day observation in rats provides information about initial healing process, not about the quality of the tissue or chances of re-injury. Most of the research originated in a single laboratory. Replication of biomechanical studies by independent groups could provide much stronger evidence.

The Achilles tendon transection was performed under ideal laboratory conditions. In real life, tendon injuries vary in severity, location, and complicating factors, making treatment outcomes less predictable.